Nordic Pharma Inc. Enhances Offerings After Treating 100,000 Patients in the USA

Nordic Pharma Inc. Expands Offerings to Celebrate Treating 100,000 Patients

In a significant milestone, Nordic Pharma Inc., a subsidiary of Nordic Group B.V., proudly announces it has successfully treated over 100,000 patients in less than two years with its innovative Lacrifill® Gel for dry eye symptoms. To celebrate this achievement, the company is now enhancing its product offerings by including cannulas with the shipments of their Lacrifill® gel syringes, responding to direct feedback from healthcare professionals.

This bold move aims to increase the convenience for eye care specialists and improve patient outcomes. According to many practitioners, incorporating cannulas has improved the gel's application process, thus receiving favorable feedback from the medical community. As stated by acclaimed ophthalmologist Dr. Eric Donnenfeld, the gel has significantly contributed to better management of the ocular surface health and comfort following surgeries.

Lacrifill® is designed to temporarily block tear drainage by occluding the canalicular system, which lengthens the time the gel remains effective on the ocular surface. Introduced to the U.S. market in May 2024 after receiving FDA approval, the product's rapid acceptance among optometrists and ophthalmologists is encouraging.

"As eye care professionals, it is our responsibility to actively manage our patients' ocular surface health and comfort, especially in the surgical context. Lacrifill® has consistently met this need, providing substantial control over ocular surface conditions," Dr. Donnenfeld stated during the announcement.

Furthermore, Dr. Mile Brujic from Premier Vision Group echoed similar sentiments highlighting the gel's importance not only for everyday care but also for surgical management, indicating that Lacrifill has transformed how they treat patients suffering from dry eye syndrome.

The gel comes in pre-filled syringes designed for easy treatment of both upper and lower canaliculi of the eyes. Each shipment now includes ten cannulas per pack, ensuring that medical professionals have a complete set for patient management.

Dr. Jai Parekh, the Chief Commercial Officer for Eye Care US, expressed satisfaction with the rapid uptake of Lacrifill, stating it has quickly become a go-to treatment for nearly 6.8% of American adults experiencing dry eye symptoms. The swift patient response to the intervention highlights its effectiveness.

Live demonstrations showcasing Lacrifill's ocular surface preparation techniques will be held during the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting set to take place from April 10-13 in Washington, D.C. Attendees will witness firsthand how the product is administered and can learn about its application from leading experts in the field.

In summary, Nordic Pharma Inc.'s expansion in response to the successful treatment of over 100,000 patients reflects a commitment to improving ocular care through innovative solutions. By enhancing its product line with the introduction of cannulas, they not only facilitate better application but also ensure that patients receive the highest quality of care available. To learn more about the Lacrifill® Canalicular Gel, visit lacrifill.com.